New drug 9MW1911 tested for safety in first human trial

NCT ID NCT05803902

First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 34 times

Summary

This Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. Participants received either the drug or a placebo by IV infusion. The study aims to find the maximum safe dose and understand how the drug moves through the body. This is early research for potential treatments of asthma, COPD, and atopic dermatitis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Peking Union Hospital

    Beijing, Beijing Municipality, 100000, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

9MW1911 injection

What this could lead to

If successful, this could lead to a new treatment option for asthma, COPD, or atopic dermatitis.

What could go wrong

This is an early Phase 1 trial in healthy people, so it does not test effectiveness. The drug may cause side effects or fail in later studies.

Conditions

The condition(s) this trial relates to.

asthma atopic eczema chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.